SCHEMBL4658499

SCHEMBL4658499

Cc1c(CCN)c2cc(O)ccc2n1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 1/20 0.56
CYP1A2 P05177 3/20 0.50
CYP3A4 P08684 3/20 0.50
CYP2D6 P10635 3/20 0.50
CYP2C9 P11712 2/20 0.50
HTR1D P28221 2/20 0.50
HTR7 P34969 2/20 0.50
HTR3A P46098 2/20 0.50
HTR6 P50406 2/20 0.50
CYP2C19 P33261 2/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
BCHE P06276 2/20 0.44
ACHE P22303 2/20 0.44
NPSR1 Q6W5P4 2/20 0.42
RAD52 P43351 1/20 0.42
BLM P54132 1/20 0.42
PLA2G2A P14555 2/20 0.40
PTGS1 P23219 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10771285 0.83 PLA2G4A (0.40) SPRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL2999508 0.81 SPR (0.39) SPRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL29206563 0.81 HTR2A (0.41) SPRCYP1A2CYP3A4CYP2D6HTR6
SCHEMBL11252321 0.81 SPR (0.53) SPRBCHEACHEPLA2G2AGAA
SCHEMBL18509545 0.81 SPR (0.59) SPRHSD17B10BCHEACHEPLA2G2A
SCHEMBL25416151 0.79 CYP1A2 (0.58) SPRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL2701682 0.79 ADRB2 (0.56) SPRCYP1A2CYP2D6HTR1DHTR7
SCHEMBL12721348 0.79 SPR (0.54) SPRBCHEACHEPLA2G2APTGS1
SCHEMBL335711 0.77 GPR3 (0.52) CYP2C19HSD17B10TDP1NPSR1GAA
SCHEMBL23777834 0.76 POLB (0.62) SPRCYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001877-A1 METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT Bioniqs Limited (GB) 2008-12-17 EP claimed
WO-2007110637-A1 METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT BIONIQS LIMITED (GB) 2007-10-04 WO claimed
CN-1938018-A Use of compounds capable of increasing serum IGF-1 levels for the preparation of therapeutic compositions for the treatment of various disease states associated with decreased IGF-1 serum levels in humans and animals VEIJLEN LTD (AN) 2007-03-28 CN claimed
CN-116814668-A Biosynthesis method of N-methyl serotonin and N-N-dimethyl serotonin 福建师范大学 2023-09-29 CN disclosed
CN-116761599-A Deuterated or partially deuterated N, N-dimethyltryptamine compounds 斯玛尔药物有限公司 2023-09-15 CN disclosed
CN-113968810-B Preparation method of N, N-dimethyl-5-hydroxytryptamine 河北维达康生物科技有限公司 2023-06-16 CN disclosed
US-20230149293-A1 INJECTABLE AND INHALABLE FORMULATIONS CYBIN UK LTD (GB) 2023-05-18 US disclosed
CN-107018997-B A method of fly spray is prepared using fly agaric Yanbian Dekang Biological Technology Co., Ltd. (CN) 2019-10-29 CN disclosed
US-20160031812-A1 SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN SOLACE PHARMACEUTICALS UK LTD. (GB) 2016-02-04 US disclosed
US-20160031812-A1 SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN SOLACE PHARMACEUTICALS UK LTD. (GB) 2016-02-04 US disclosed
US-9169234-B2 Sepiapterin reductase inhibitors for the treatment of pain CHILDREN'S MEDICAL CENTER CORPORATION (US) 2015-10-27 US disclosed
US-9169234-B2 Sepiapterin reductase inhibitors for the treatment of pain CHILDREN'S MEDICAL CENTER CORPORATION (US) 2015-10-27 US disclosed
US-20120322800-A1 Sepiapterin Reductase Inhibitors For The Treatment of Pain SOLACE PHARMACEUTICALS UK LTD. (GB) 2012-12-20 US disclosed
US-20120322800-A1 Sepiapterin Reductase Inhibitors For The Treatment of Pain SOLACE PHARMACEUTICALS UK LTD. (GB) 2012-12-20 US disclosed
WO-2011047156-A1 SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN HERCULES TECHNOLOGY MANAGEMENT CO V, INC. (US) 2011-04-21 WO disclosed
CN-1938018-B Use of compounds for the preparation of compositions for the treatment of various disease states in humans and animals associated with reduced IGF-1 serum levels VEIJLEN LTD 2010-09-01 CN disclosed
CN-1938018-A Use of compounds capable of increasing serum IGF-1 levels for the preparation of therapeutic compositions for the treatment of various disease states associated with decreased IGF-1 serum levels in humans and animals VEIJLEN LTD (AN) 2007-03-28 CN disclosed
CN-1870992-A Animal feed composition VEIJLEN N V (AN) 2006-11-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031812-A1 SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN SPR, QDPR, SRR SPR 1/4885CYP1A2 444/4885CYP3A4 258/4885
US-20120322800-A1 Sepiapterin Reductase Inhibitors For The Treatment of Pain SPR, QDPR, SRR SPR 1/4885CYP1A2 444/4885CYP3A4 258/4885
US-20230149293-A1 INJECTABLE AND INHALABLE FORMULATIONS HTR5A, HTR1B, HTR2B SPR 3558/4885CYP1A2 1346/4885CYP3A4 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.